Clinical Trial Detail

NCT ID NCT02259582
Title A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements yes
Sponsors OncoMed Pharmaceuticals, Inc.
Indications

non-small cell lung carcinoma

Therapies

Carboplatin + Pemetrexed

Demcizumab

Age Groups: adult

Additional content available in CKB BOOST